公开(公告)号：US20180311372A1

公开(公告)日：2018-11-01

申请号：US15872841

申请日：2018-01-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  C07K16/28 ,  A61P3/10

CPC classification number: C07K16/28 ,  A61K39/395 ,  A61P3/10

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20160053000A1

公开(公告)日：2016-02-25

申请号：US14839662

申请日：2015-08-28

Applicant: AMGEN INC.

Inventor： Shu-Chen LU ,  Minghan WANG

IPC: C07K16/18 ,  A61K9/00

CPC classification number: C07K16/18 ,  A61K9/0019 ,  A61K9/0048 ,  A61K39/395 ,  A61K39/3955 ,  A61K2039/505 ,  C07H21/02 ,  C07K14/515 ,  C07K16/26 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/09 ,  C12N15/11 ,  C12P21/02 ,  G01N33/53 ,  G01N33/74 ,  G01N2800/7014

Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.

Abstract translation: 本公开涉及apelin抗原结合蛋白和使用apelin抗原结合蛋白的方法。 抗原结合蛋白可以包含对apelin的抗体，并且可以用于治疗涉及血管发生的病理状况。 病理状况可能包括癌症或视网膜病变和/或视网膜病变相关并发症。

公开(公告)号：US20250121056A1

公开(公告)日：2025-04-17

申请号：US18982197

申请日：2024-12-16

Applicant: AMGEN INC.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle M. VENIANT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K39/395 ,  A61K47/68 ,  A61P3/10 ,  C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

公开(公告)号：US20210154318A1

公开(公告)日：2021-05-27

申请号：US17151045

申请日：2021-01-15

Applicant: Amgen Inc.

Inventor： Yuan CHENG ,  Chawita NETIROJJANAKUL ,  Jerry Ryan HOLDER ,  Bin WU ,  James R. FALSEY ,  Bradley J. HERBERICH ,  Kelvin SHAM ,  Leslie P. MIRANDA ,  Shu-Chen LU ,  Murielle VENIENT-ELLISON ,  Shanaka STANISLAUS ,  Junming YIE ,  Jing XU

IPC: A61K47/68 ,  A61P3/10 ,  C07K16/28 ,  A61K39/395

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.